The concurrent modulation of the tumor microenvironment by both DNA-PKcs inhibitors and immunotherapy presents a unique opportunity to potentiate radiotherapy efficacy, prompting the initiation of several clinical trials (NCT04068194, NCT04071236) investigating this triple-combination therapeutic strategy that simultaneously targets DNA damage response pathways and immune checkpoint mechanisms. The gene discussed is PRKDC; the disease is neoplasm.